Meredith M. Regan

Oct 2, 2024 | digitalcommons.library.tmc.edu | Jennifer K. Litton |Meredith M. Regan |Lajos Pusztai |Hope Rugo

PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points.

Jul 11, 2023 | fal.cn | Jennifer K. Litton |Meredith M. Regan |Lajos Pusztai |Hope Rugo

Jennifer K.

Jul 11, 2023 | ascopubs.org | Jennifer K. Litton |Meredith M. Regan |Hope Rugo |Sara M. Tolaney

Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us. Because we respect your right to privacy, you can choose not to allow some or all types of cookies.